Biotechnology in the Time of COVID-19: Commentaries from the Front Line

by Jeremy M. Levin

We believe that antibodies that cross-react with an entire viral family, and therefore recognize an epitope that is highly conserved, are likely to have advantages as therapeutic agents because resistant mutants are less likely to arise.